ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Lupin Limited received an ESG rating of '60' ('Adequate' category) from ESG Risk Assessments & Insights Limited, which was assigned independently without company engagement.
Lupin Ltd has submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended June 30, 2026. This disclosure details the current equity distribution structure.
Lupin Limited announced that the acquisition of minority shareholding in Multicare Pharmaceuticals Philippines is ongoing. Completion is now expected in July 2026, pending closing conditions.
Lupin shared positive Phase 1 trial results for its novel SOS1 inhibitor, LNP8701, at ASCO 2026. The drug demonstrated safety and favorable anti-tumor activity in metastatic patients.
Lupin Limited filed its Annual Secretarial Compliance Report for FY2026. The report by Makarand M. Joshi & Co. confirms regulatory adherence with no major non-compliances noted.
Lupin debuted in the Dow Jones Best-in-Class Indices for 2026. This prestigious inclusion recognizes the company's industry-leading ESG performance and sustainability leadership.
Lupin Ltd announced the conclusion of a U.S. FDA inspection at its Somerset, New Jersey facility. The inspection, held from April 13-17, 2026, resulted in a Form-483 with three observations. The company plans to address these observations within the stipulated timeframe and remains committed to CGMP standards.